Shire entered a deal with Rani Therapeutics to develop an orally delivered therapy for patients with hemophilia A using Rani's Pill technology. Under the agreement, Shire gets an exclusive licensing option to develop and commercialize the technology to deliver factor VIII treatment upon completion of feasibility studies.
Shire collaborates with Rani on hemophilia A drug study
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.